Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Cinacalcet recalled?

Yes — there is an active recall. 22 ongoing FDA recalls mention Cinacalcet (31 total). Check the affected lots below.

Most common reason: Nitrosamine impurity (23 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Cinacalcet. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Cinacalcet recalls in 2026

9 initiated in 2026, 31 in total — newest first
Class II · Moderate risk

Cinacalcet Tablets

CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

Ongoing Nitrosamine impurity AvKARE NDC 42291-461-30 D-0110-2025
Class II · Moderate risk

Cinacalcet Tablets

CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

Ongoing Nitrosamine impurity AvKARE NDC 42291-460-30 D-0109-2025
Class II · Moderate risk

Cinacalcet Tablets

CGMP deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake limit.

Ongoing Nitrosamine impurity AvKARE NDC 42291-459-30 D-0108-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-833-30 D-0079-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-832-30 D-0078-2025
Class II · Moderate risk

Cinacalcet Tablets

cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Aurobindo Pharma USA Inc NDC 65862-831-30 D-0077-2025
Class II · Moderate risk

Cinacalcet Tablets

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Terminated Nitrosamine impurity Accord Healthcare, INC. D-0032-2025
Class II · Moderate risk

Cinacalcet Tablets

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Terminated Nitrosamine impurity Accord Healthcare, INC. D-0031-2025
Class II · Moderate risk

Cinacalcet Tablets 30 mg

CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

Terminated Nitrosamine impurity Accord Healthcare, INC. D-0030-2025
Class II · Moderate risk

Cinacalcet Tablets

CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit

Ongoing Nitrosamine impurity Dr. Reddy's Laboratories, Inc. NDC 43598-369-30 D-0028-2025